Octopus Overlords

Max Peck wrote: Thu Sep 16, 2021 3:18 pm My first take on Vaxevria was that it sounds like an STD. Or possibly a villain from a Power Rangers serial.

I suppose either of those isn't entirely incompatible with TheFalconer's take...

dbt1949 wrote: Sun Sep 19, 2021 11:52 pm Does that take place 8 months after the second shot or any time now?

What is the reason for that? Want to vaccinate more people first?

Zaxxon wrote: Mon Sep 20, 2021 10:05 am Haven't seen this posted yet: Pfizer is out with a press release this AM confirming that their vaccine is safe and effective in children 5-11. This was an expected step prior to them submitting for EUA approval. This release also confirms that they still expect to submit that application by the end of this month.

So, hopefully late October for approval?

The company has also estimated that it will be ready to submit vaccine data for even younger children—ages 6 months to 5 years—about a month later, in the early November timeframe. If all goes well, that could put vaccine availability for that youngest group around the start of December.

stessier wrote: Mon Sep 20, 2021 10:21 am Look like I'll be working from home for most of this week.

4 steps that have to happen before Covid-19 vaccine is available for children ages 5 to 11

Data collected from 18 states between March and August suggest the Pfizer-BioNTech vaccine reduces the risk of being hospitalized with COVID-19 by 91% in the first four months after receiving the second dose. Beyond 120 days, however, that vaccine efficacy drops to 77%.

Meanwhile, Moderna’s vaccine was 93% effective at reducing the short-term risk of COVID-19 hospitalization and remained 92% effective after 120 days.

Overall, 54% of fully vaccinated Americans have been immunized with the Pfizer shot.

FishPants wrote: Tue Sep 21, 2021 2:24 pm Interesting that boosters were voted against, yet there's this tidbit in the news today.

Data collected from 18 states between March and August suggest the Pfizer-BioNTech vaccine reduces the risk of being hospitalized with COVID-19 by 91% in the first four months after receiving the second dose. Beyond 120 days, however, that vaccine efficacy drops to 77%.

Meanwhile, Moderna’s vaccine was 93% effective at reducing the short-term risk of COVID-19 hospitalization and remained 92% effective after 120 days.

Overall, 54% of fully vaccinated Americans have been immunized with the Pfizer shot.

If Israel was seeing a marked increase in hospitalization rate in fully vaxxed that was mitigated with a third shot -- doesn't that basically underscore the need to boost (at least apparently for Pfizer only, not for Moderna?).

The Food and Drug Administration authorized a booster dose Wednesday of the Pfizer-BioNTech COVID vaccine for people 65 and older and others at high risk of severe COVID disease.

The FDA says the vaccine can also be given to people ages 18 to 64 whose jobs or institutional exposure to the coronavirus puts them at high risk of serious complications of COVID-19.

A third shot of the vaccine can be given at least six months after completion of the two-dose regimen of the Pfizer-BioNTech vaccine, according to the authorization.

certain populations such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons, among others,

Smoove_B wrote:U.S. Pfizer booster has green light:

The Food and Drug Administration authorized a booster dose Wednesday of the Pfizer-BioNTech COVID vaccine for people 65 and older and others at high risk of severe COVID disease.

The FDA says the vaccine can also be given to people ages 18 to 64 whose jobs or institutional exposure to the coronavirus puts them at high risk of serious complications of COVID-19.

A third shot of the vaccine can be given at least six months after completion of the two-dose regimen of the Pfizer-BioNTech vaccine, according to the authorization.

They give examples of jobs and institutional exposures such as:

certain populations such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons, among others,

NEW: Pfizer is ready to ask the FDA for authorization to use its Covid-19 vaccine in children 5-11 “within days,” Pfizer CEO Albert Bourla told ABC.

Laboratory studies show that Merck & Co's (MRK.N) experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday.

Since molnupiravir does not target the spike protein of the virus - the target of all current COVID-19 vaccines - which defines the differences between the variants, the drug should be equally effective as the virus continues to evolve, said Jay Grobler, head of infectious disease and vaccines at Merck.

Molnupiravir instead targets the viral polymerase, an enzyme needed for the virus to make copies of itself. It is designed to work by introducing errors into the genetic code of the virus.

Data show that the drug is most effective when given early in the course of infection, Merck said.

Smoove_B wrote: Wed Sep 29, 2021 12:47 pm Still no word on approvals for 5-11 year olds, but hopefully this week!

No word on if it's apple flavored, but here's hoping it's available soon.

Unagi wrote: Tue Sep 14, 2021 4:49 pm So, my 11 yr old daughter had a small headache this morning and went into the nurses office.
I guess 'just a headache' is indeed how a majority of kids experience COVID, so the nurse was alarmed (I didn't even know she had one).

She's pulled from school now, I got her tested, and she's now home until the results of a lab test come back negative... (none of that fancy rapid-test crap).
We should know in 48 hours.

Her headache is basically gone now... but, it's indeed rare that she even has a headache, so I'm only 50/50 I guess on what to expect.